CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10,644 enrolled
Drug / intervention
GeneXpert I +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03044158
NCT03044158N/ACompleted

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care: The XPEL-TB Trial

University of California, San Francisco·interventional·Posted Feb 6, 2017·Updated Feb 18, 2025

In Brief

A clinical study evaluating GeneXpert I, Process re-design, and 1 other intervention for Tuberculosis, Pulmonary and Rifampicin Resistant Tuberculosis. Completed, enrolled 10,644 participants across 20 sites.

Detailed Summary

The investigators' overall objective is to assess the effectiveness, implementation and costs of a streamlined TB diagnostic evaluation strategy based around rapid, onsite molecular testing. The intervention strategy was developed based on theory-informed assessment of barriers to TB diagnostic evaluation at community health centers in Uganda and a process of engagement with local stakeholders. It includes: 1) Point-of-care molecular testing using GeneXpert as a replacement for sputum smear microscopy; 2) Re-structuring of clinic-level procedures to facilitate same-day TB diagnosis and treatment; and 3) Quarterly feedback of TB evaluation metrics to health center staff. The investigators' central hypothesis is that the intervention strategy will have high uptake and increase the number of patients diagnosed with and treated for active pulmonary TB. To test this hypothesis, the investigators will conduct a pragmatic cluster-randomized trial at community health centers that provide TB microscopy services in Uganda in partnership with the National TB Program (NTP). The investigators utilize an effectiveness-implementation hybrid design in which, concurrent with the clinical trial, the investigators will conduct nested mixed methods, health economic and modeling studies to assess 1) whether the intervention strategy modifies targeted barriers to TB diagnostic evaluation; 2) fidelity of implementation of the intervention components (i.e, the degree to which intervention components were implemented as intended vs. adapted across sites); and 3) cost-effectiveness and public health impact.

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 6, 2017
Enrollment StartOct 22, 2018
Primary CompletionMar 31, 2020
Study CompletionJul 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.4 years ago

Interventions

GeneXpert Idevice

Onsite molecular testing with GeneXpert I as a replacement for microscopy

Process re-designbehavioral

Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.

Performance Feedbackother

Feedback of TB diagnostic evaluation quality indicators to health center staff